Upfront Chemohormonal Therapy for Prostate Cancer: Neutropenia and G-CSF Use.
Keywords:
neutropenia, GCS-F, chemohormonal therapy, docetaxel, prostate cancer, CHAARTEDAbstract
After the publication of the results of CHAARTED trial, we discuss an issue of clinical interest about toxicity of this treatment and its prophylactic management. The low rates of neutropenia reported in CHAARTED trial population, compared to those of similar previous studies, need further clarifications about the use of G-CSF, not described by the authors, in order to reproduce this hematological tolerability also in everyday clinical practice. We highlighted the importance of toxicity management and prevention in order to better apply the results of this promising trial in real life patient care.
Downloads
Published
Issue
Section
License
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Transfer of Copyright and Permission to Reproduce Parts of Published Papers.
Authors retain the copyright for their published work. No formal permission will be required to reproduce parts (tables or illustrations) of published papers, provided the source is quoted appropriately and reproduction has no commercial intent. Reproductions with commercial intent will require written permission and payment of royalties.